Evidence map›Paper›PMID 41999030›Full record

Trial reportJournal of hepato-biliary-pancreatic sciences2026

Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial.

Dongha Lee, Yukiyasu Okamura, Yoshihide Nanno, Takuya Mizumoto, Jun Ishida, Naoto Gotohda, Hirochika Toyama, Akira Fukutomi, Narikazu Boku, Katsuhiko Uesaka

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of hepato-biliary-pancreatic sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dongha LeeDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Yukiyasu OkamuraDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo, Japan.
Yoshihide NannoDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Takuya MizumotoDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.ORCID https://orcid.org/0000-0002-8665-2776
Jun IshidaDivision of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.ORCID https://orcid.org/0000-0001-7550-448X
Naoto GotohdaDepartment of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan.ORCID https://orcid.org/0000-0002-4468-5844
Hirochika ToyamaDepartment of Surgery, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.
Akira FukutomiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
Narikazu BokuDepartment of Oncology and General Medicine, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Minato-ku, Tokyo, Japan.
Katsuhiko UesakaDivision of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.

Funding

Pharma-Valley Center, Shizuoka Industrial Foundation (currently The Mt. Fuji Foundation for Healthcare Innovation and Cluster Development), and Taiho Pharmaceutical
6 · The paper itself

Abstract

backgroundRelationship between timing of initiating adjuvant chemotherapy (AC) and clinical outcomes after surgery for pancreatic cancer remains controversial.

methodsIn this ancillary analysis of the JASPAC 01 trial, 187 patients were classified according to the interval between surgery and chemotherapy initiation to Early (< 6 weeks, n = 45), Standard (6-8 weeks, n = 70), and Delayed (> 8 weeks, n = 72). Overall survival (OS) and relapse-free survival (RFS) were analyzed.

resultsBaseline characteristics were comparable among three groups. The Standard group showed significantly longer OS than the Early group (median, 66 vs. 37 months; HR 0.61, 95% CI 0.38-0.99; p = 0.041), and relatively longer OS compared with the Delayed group (median, 45 months; HR 0.68, 95% CI 0.44-1.05; p = 0.077). RFS was longer in the Standard group (median, 46 months) compared with the Early group (20 months; HR 0.61, 95% CI 0.38-0.99; p = 0.040) and the Delayed group (20 months; HR 0.59, 95% CI 0.39-0.89; p = 0.011). Multivariate analysis identified operative procedure, R1 resection, lymph node metastasis, and nonstandard initiation (< 6 or > 8 weeks) as independent adverse prognostic factors.

conclusionsInitiation of S-1 AC at 6-8 weeks after pancreatectomy was associated with favorable survival outcomes.

Indexed as

Antimetabolites, AntineoplasticOxonic AcidPancreatectomyPancreatic NeoplasmsTegafurAgedChemotherapy, AdjuvantDisease-Free SurvivalDrug CombinationsFemaleHumansMaleMiddle AgedPrognosisSurvival RateTime FactorsAntimetabolites, AntineoplasticDrug CombinationsOxonic AcidS 1 (combination)Tegafuradjuvant chemotherapyJASPAC 01pancreatectomypancreatic cancerS‐1 timing

Identifiers

PMID41999030
PMCPMC13397153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.